Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICK-NK + T-Dxd in Advanced Breast Cancer
NCT07553390Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2026
- Primary completion
- Mar 2036
- Countries
- 1
01
Overview
Phase 1, open-label trial of TGFBR2 knockout inducible caspase 9/TROP2 chimeric antigen receptor/interleukin-15 natural killer cells in breast cancer (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
TGFBR2 knockout inducible caspase 9/TROP2 chimeric antigen receptor/interleukin-15 natural killer cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07553390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553390.